Systemic sclerosis test gets CE mark, 7/16
July 2016—Protagen gained CE marking for its Multilisa BICD2 test. BICD2 is a proprietary biomarker discovered by Protagen using the SeroTag technology platform.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
FFPE DNA repair kit, 7/16
July 2016—Oxford Gene Technology introduced its SureSeq FFPE DNA Repair Mix for repairing a broad range of damage in formalin-fixed, paraffin-embedded–derived DNA.
Embedder station, 7/16
July 2016—Tanner Scientific’s second-generation embedder station, the TN1550, with a dispensing module and separate cold plate, is now available.
Myriad Web portal, acquisition, 7/16
July 2016—Myriad Genetics launched a Web portal on ms360.myriad.com that allows patients to access their personal test results and to access other tools and ideas to help them make health care decisions. The first phase of the portal will provide access to test results for the company’s hereditary cancer and prostate cancer tests.
Qiagen adds Horizon QC, 7/16
July 2016—Qiagen announced that it will offer an extensive package of quality control data, generated through the application of Horizon Discovery Group’s reference standards, with its GeneReader NGS System.
Ultrasensitive assays, 7/16
July 2016—Aushon BioSystems has launched the Ciraplex Ultra Ultrasensitive Assays with femtogram/milliliter level detection to address multiple biomarkers in a wide range of therapeutic areas.
Automated DNA purification, 7/16
July 2016—Mawi DNA Technologies announced that Omega Bio-tek has successfully developed an automated DNA purification method from iSwab-DNA with its Mag-Bind Blood and Tissue DNA HDQ chemistry on the Hamilton MicroLabStar automation platform.
Cellular detection kit, 7/16
July 2016—The Cyto-ID Autophagy Detection Kit 2.0 from Enzo Life Sciences measures autophagic vacuoles and monitors autophagic flux in lysosomally inhibited live cells using a novel dye that selectively labels accumulated autophagic vacuoles.
Sysmex, Siemens extend partnership, 7/16
July 2016—Sysmex and Siemens Healthineers Laboratory Diagnostics announced an extension to their partnership through at least 2020.
Liquid biopsy assay, 7/16
July 2016—Foundation Medicine has launched an analytically validated and accurate blood-based circulating tumor DNA assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available.